NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Focus remains on Alzheimer's and rare disease markets. Biogen demonstrated solid performance ... to prevent any background noise. After the speakers' remarks, there will be a question and answer ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

When Biogen and its partner Eisai announced in March that they’d halted two simultaneous Phase 3 clinical trials on an Alzheimer’s drug based on disappointing preliminary data, the development was ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...

Alzheimer's deal renegotiated Meanwhile Biogen has one of the most keenly anticipated drug candidates in its pipeline, early Alzheimer’s treatment aducanumab. The firm has just renegotiated its ...

Ivana Rubino works at Biogen, 225 Binney Street ... Infrastructural barriers include training a sufficient number of Alzheimer specialists, feasibility of biomarker testing for routine clinical ...

Biogen, Inc. is a biopharmaceutical company ... ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles ...

CEO Chris Viehbacher reaffirmed Biogen’s priority of driving growth in its four recently launched drugs: Leqembi for early-stage Alzheimer’s disease, Qalsody for benign prostate cancer ...